R.PR
REGISTERED-PRINCIPAL REGISTER
06/09/2026
Back to search
Official data from USPTO
ANDEMBRY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
14
Latest update
06/09/2026
Trademark type
Combined
Nice classes
5
Filing date
01/21/2026
Registration date
06/09/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/09/2026
Last transaction
06/09/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
2025-00-00
First use in commerce
2025-00-00
Drawing code
3
Owner type
27
Owner location
Marburg, DE
Examiner
HAN, JOANNA Y
Law office
N80
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of three curved bars, yellow, blue and green, to the left of "ANDEMBRY" in blue.
Holders and representatives
Holders
CSL Behring GmbH
Representatives
Scott Woldow Smith, Gambrell & Russell, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for treating von Willebrand diseasehemophiliaprimary immunodeficiencyhereditary angioedemafibrinogen deficiencyAlpha 1 antitrypsin deficiencyinflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophiliapharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophiliapharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophiliaa blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodiesdiagnostic kits consisting primarily of monoclonal antibodiesbuffersreagents for use in disease testing; blood for medical purposes; cell cultures for medical purposescells for medical or clinical use; cell cultures for medical purposesliving cells for medical use; cell cultures for medical purposesstem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditionsrespiratory conditionspneumoniacovid-19influenza; Pharmaceutical preparationsantibody for the treatment of acute respiratory distress syndromeARDS; pharmaceutical preparationsantibody for the treatment of Idiopathic Pulmonary FibrosisIPF and Interstitial Lung DiseasesILD; Pharmaceutical preparationsantibody for the treatment of Hereditary AngioedemaHAE
Publications
History of USPTO decisions and trademark events.
14 publications found
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/21/2026
PUBO
PUBLISHED FOR OPPOSITION
04/21/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/15/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/24/2026
XAEC
EXAMINER'S AMENDMENT ENTERED
03/24/2026
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/24/2026
GNEA
EXAMINERS AMENDMENT E-MAILED
03/24/2026
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/24/2026
DOCK
ASSIGNED TO EXAMINER
03/23/2026
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
03/23/2026
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/23/2026
MAFR
APPLICATION FILING RECEIPT MAILED
01/21/2026
NWAP
NEW APPLICATION ENTERED
01/21/2026
Continuous trademark protection
Get notified about every new filing that threatens ANDEMBRY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.